Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus ...

Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year ...

Abbott expects the test to be available in emergency rooms and urgent care centers this summer. A blood test designed to aid in the rapid diagnosis of concussions has gained FDA approval.

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott Laboratories ABT ... Toxicology and Consumer Diagnostics. In rapid and point-of-care diagnostics businesses, the company is consistently expanding its test menus and is also capitalizing ...

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT ... excluding COVID-19 testing-related sales. Fourth-quarter GAAP diluted EPS of $5.27 and adjusted diluted EPS of $1.34, which excludes specified ...

Robust Market Growth: The global rapid test readers market is projected to grow at a CAGR of 8.8% from 2023 to 2033, ...